Discover
ABCL
AbCellera Biologics Inc.
12.63
2 x 8.24
2 x 14.72
bid
ask
-
0.10
0.79%
2 @ 07:59 PM
12.70 +0.07 (0.54%)
| Ytd | 269.30% | |
| 1y | 167.58% |
12.37
day range
12.96
2.78
52 week range
12.73
| Open | 12.56 | Prev Close | 12.73 | Low | 12.37 | High | 12.96 | Mkt Cap | 4.09B |
| Vol | 5.44M | Avg Vol | 7.49M | EPS | -0.54 | P/E | N/A | Forward P/E | -17.66 |
| Beta | 1.32 | Short Ratio | 3.49 | Inst. Own | 36.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 9.00 | 200-d Avg | 5.45 | 1yr Est | 17.13 |
| Income Statement | |||
| Total Revenue | 4.05M | ||
| Revenues (USD) | 4.05M | ||
| Gross Profit | 4.05M | ||
| Operating Expenses | 66.83M | ||
| Research and Development Expense | 45.99M | ||
| Selling, General and Administrative Expense | 13.85M | ||
| Operating Income | -62.78M | ||
| Interest Expense | 42.00K | ||
| Income Tax Expense | -3.54M | ||
| Net Income | -55.43M | ||
| Net Income Common Stock | -55.43M | ||
| Net Income Common Stock (USD) | -55.43M | ||
| Consolidated Income | -55.43M | ||
| Earnings per Basic Share | -0.18 | ||
| Earnings per Basic Share (USD) | -0.18 | ||
| Earnings per Diluted Share | -0.18 | ||
| Earning Before Interest & Taxes (EBIT) | -58.92M | ||
| Earning Before Interest & Taxes (USD) | -58.92M | ||
| Weighted Average Shares | 305.56M | ||
| Weighted Average Shares Diluted | 305.56M | ||
| Balance Sheet | |||
| Cash and Equivalents | 145.07M | ||
| Cash and Equivalents (USD) | 145.07M | ||
| Investments | 485.27M | ||
| Investments Current | 420.04M | ||
| Investments Non-Current | 65.23M | ||
| Trade and Non-Trade Receivables | 18.60M | ||
| Current Assets | 679.23M | ||
| Property, Plant & Equipment Net | 416.68M | ||
| Total Assets | 1.31B | ||
| Total Debt | 129.95M | ||
| Current Liabilities | 53.19M | ||
| Debt Non-Current | 129.95M | ||
| Total Liabilities | 411.56M | ||
| Accumulated Retained Earnings (Deficit) | -128.07M | ||
| Accumulated Other Comprehensive Income | -3.15M | ||
| Shareholders Equity | 896.02M | ||
| Shareholders Equity (USD) | 896.02M | ||
| Assets Non-Current | 628.35M | ||
| Total Debt (USD) | 129.95M | ||
| Deferred Revenue | 61.16M | ||
| Goodwill and Intangible Assets | 84.34M | ||
| Liabilities Non-Current | 358.37M | ||
| Trade and Non-Trade Payables | 32.48M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 8.78M | ||
| Net Cash Flow from Financing | 6.39M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 43.23M | ||
| Capital Expenditure | -2.13M | ||
| Issuance (Repayment) of Debt Securities | -7.19M | ||
| Net Cash Flow from Investing | 11.34M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 7.88M | ||
| Net Cash Flow from Operations | 25.92M | ||
| Effect of Exchange Rate Changes on Cash | -430.00K | ||
| Share Based Compensation | 12.29M | ||